Nuvation Bio Inc logo

Nuvation Bio Inc

NUVB
Healthcare|Biotechnology|USA
$5.81
-0.30 (-4.91%)
Tangible Book
$0.89

About

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.

Stock Price

+151.5%(1Y)

Pipeline Summary

18 total trials
9
Phase 1
6
Phase 2
3
Phase 3
0
Phase 4
Active: 3Completed: 5Recruiting: 4Withdrawn: 2Terminated: 3NO_LONGER_AVAILABLE: 1

Active Trials (7)

A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene
NCT04395677Non Small Cell Lung Cancer
Phase 2Active
Enrollment: 173 participants
CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)
NCT04151342Cancer
Recruiting
Enrollment: 5,500 participants
Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC
NCT04919811Non Small Cell Lung Cancer
Phase 2Active
Enrollment: 217 participants
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
NCT05303519Glioma
Phase 3Recruiting
Enrollment: 365 participants
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
NCT06564324Non Small Cell Lung Cancer
Phase 3Recruiting
Enrollment: 194 participants
View all 7 active trials →

BioScore

4.8/10
Cautious

Ownership

Recent Insider Trades

Markel StacySELL
2026-06-23125,000 shares @ $6.03
Wentworth KerrySELL
2026-06-2363,000 shares @ $6.02
Sauvage PhilippeSELL
2026-06-2347,668 shares @ $6.01
Mashal RobertBUY
2026-06-0925,000 shares @ $4.73
Wentworth KerrySELL
2026-04-1736,750 shares @ $5.01

Recent News

2026-07-07 16:40:00
2026-07-07 13:05:41
2026-07-06 22:02:00
2026-07-06 22:00:03
2026-06-29 13:00:17
Data last updated: Jul 13, 2026, 12:43 PM